↓ Skip to main content

Dove Medical Press

Article Metrics

Age-old wisdom concerning cell-based therapies with added knowledge in the stem cell era: our perspectives

Overview of attention for article published in Stem cells and cloning advances and applications, April 2013
Altmetric Badge

Mentioned by

facebook
1 Facebook page

Citations

dimensions_citation
2 Dimensions

Readers on

mendeley
5 Mendeley
Title
Age-old wisdom concerning cell-based therapies with added knowledge in the stem cell era: our perspectives
Published in
Stem cells and cloning advances and applications, April 2013
DOI 10.2147/sccaa.s41798
Pubmed ID
Authors

Samuel Abraham, Preethy, John, Jegatheesan Saravana Ganesh, Srinivasan, Terunuma, Iwasaki

Abstract

Among the various strategies providing a cure for illness, cell-based therapies have caught the attention of the world with the advent of the "stem cell" era. Our inherent understanding indicates that stem cells have been in existence since the birth of multicellular organisms. However, the formal discovery of stem cells in the last century, followed by their intricate and extensive analysis, has led to clinical and translational efforts with the aim of using them in the treatment of conditions which don't have a definitive therapeutic strategy, has fueled our interest and expectations. Technological advances in our ability to study their cellular components in depth, along with surface markers and other finer constituents, that were unknown until last century, have improved our understanding, leading to several novel applications. This has created a need to establish guidelines, and in that process, there are expressed understandings and views which describe cell therapy along lines similar to that of biologic products, drugs, and devices. However, the age-old wisdom of using cells as tools for curing illness should not be misled by recent knowledge, to make cell therapy using highly complex stem cells equal to factory-synthesized and reproducible chemical compounds, drugs, or devices. This article analyses the differences between these two entities from various perspectives.

Mendeley readers

The data shown below were compiled from readership statistics for 5 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 5 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 1 20%
Unknown 4 80%
Readers by discipline Count As %
Materials Science 1 20%
Unknown 4 80%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 January 2014.
All research outputs
#11,078,693
of 12,460,262 outputs
Outputs from Stem cells and cloning advances and applications
#35
of 43 outputs
Outputs of similar age
#190,331
of 229,525 outputs
Outputs of similar age from Stem cells and cloning advances and applications
#5
of 6 outputs
Altmetric has tracked 12,460,262 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 43 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.5. This one scored the same or higher as 8 of them.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 229,525 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one.